Floatz logo

Rgx-121

Mucopolysaccharidosis Type II (MPS II)

REGENXBIO Inc.gene_therapyPhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Mucopolysaccharidosis Type II (MPS II) cohort.

Asset / SponsorPhaseRating
gc1111
Takeda
Phase 4A
PABINAFUSP ALFA
JCR Pharmaceuticals Co., Ltd.
Phase 3BBB
Idursulfase Beta
GC Biopharma Corp
Phase 3BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Takeda
Phase 4BB
Gnr-055
AO GENERIUM
Phase 2/3BB

View all 32 →

Same molecule, other indications

Rgx-121 is also rated in:

mucopolysaccharidosis type 2Dormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →